| Primary | Proportion of Participants With Majority Reader Self-agreement in Ischemia Assessment Between First and Second Stress Scans | SPECT scans were reviewed in a blinded fashion by 3 independent expert readers using the 17-segment model for standardized myocardial segmentation. At rest and stress, each segment was scored on a 0 (normal) to 4 (absent contrast/radiotracer uptake) scale by each of the 3 blinded readers according to the amount of contrast or radiotracer the myocardium in the segment absorbed. If the stress score was ≥ 2 and the rest score was less than the stress score, the segment was counted as having a reversible defect. The number of segments with reversible defects was categorized as absence (0 - 1 reversible segments) or presence (≥ 2 defects reversible segments) of ischemia. Each reader was defined as having self-agreement based upon identical categorization of a given participant as absent or present for ischemia for both the initial and second stress visits. Majority agreement is if at least 2 out of the 3 blinded readers demonstrated self-agreement for a given participant. | | Posted | | Number | 95% Confidence Interval | proportion of participants | | Day 1 (rest scan and first stress scan) and Day 2 -15 (second stress scan) | | | | ID | Title | Description |
|---|
| OG000 | Regadenoson After Peak Exercise | On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI. | | OG001 | Regadenoson Alone | On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI. |
| | | Title | Denominators | Categories |
|---|
| | | Title | Measurements |
|---|
| - OG0000.92(0.89 to 0.94)
- OG0010.95(0.93 to 0.97)
|
|
| | Group IDs | Group Description | Statistical Method | Statistical Comment | P-Value | P-Value Comment | Parameter Type | Parameter Value | Dispersion Type | Dispersion Value | Confidence Interval Sides | Confidence Interval % | CI Lower Limit | CI Upper Limit | CI Lower Limit Comment | CI Upper Limit Comment | Estimate Comment | Tested Non-Inferiority | Non-Inferiority Type | Non-Inferiority Comment | Other Analysis Description |
|---|
| | | | | | Difference | -0.03 | Standard Error of the Mean | 0.015 | 2-Sided | 95 | -0.06 | -0.00 | | | Difference equals Regadenoson After Peak Exercise minus Regadenoson Alone | Yes | Non-Inferiority or Equivalence | If the lower confidence bound of the 1-sided alpha level of 0.025 of the difference in the proportion of participants with majority reader self-agreement exceeded -0.075, non-inferiority would be demonstrated. | |
|
| Secondary | Percentage of Participants With Treatment-emergent Clinically Significant Cardiac Events | A clinically significant cardiac event is defined as: Or
- a treatment-emergent adverse event (TEAE) per the Medical Dictionary for Regulatory Activities (MedDRA) Standardised MedDRA Queries (SMQ) (Narrow Scope) for myocardial infarction
Or
- a TEAE preferred term of angina unstable within 24 hours of regadenoson administration.
| Safety analysis set (all randomized participants who received at least 1 dose of regadenoson study drug) | Posted | | Number | | percentage of participants | | Within 1 hour for ECG events and up to 24 hours for adverse events after administration of regadenoson | | | | ID | Title | Description |
|---|
| OG000 | Regadenoson After Peak Exercise: MPI 1 | On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI. | | OG001 | Regadenoson After Peak Exercise: MPI 2 | |
|
| Secondary | Proportion of Participants With Agreement in the Assessment of Absence or Presence of Ischemia Between First and Second Stress Scans | The number of segments with reversible defects was assessed by each of the 3 blinded independent expert readers. Based on the median count of the number of reversible defects across the 3 readers, categorized as absence (0 to 1 reversible segments) or presence (≥ 2 reversible defects) of ischemia, the proportion of participants with agreement in the presence and absence of ischemia between the first and second stress scans was calculated. | | Posted | | Number | 95% Confidence Interval | proportion of participants | | Day 1 (stress MPI 1) and Day 2 -15 (stress MPI 2) | | | | ID | Title | Description |
|---|
| OG000 | Regadenoson After Peak Exercise | On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI. | | OG001 | Regadenoson Alone | On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI. |
| |
| Secondary | Proportion of Participants With Agreement in the Assessment of Reversible Defects in 3 Categories of Ischemia Between First and Second Stress Scans | The number of segments with reversible defects was assessed by each of the 3 blinded independent expert readers. Based on the median count of the number of reversible defects across the 3 readers, categorized as 0 to 1, 2 to 4, or ≥ 5 reversible segments, the proportion of participants with agreement in the three ischemia categories between the first and second stress scans was to be calculated. In the reported data, these proportions only include the 0-1 and 2-4 categories; the ≥ 5 category was not included because there were no participants in this category for the Regadenoson Alone group for the initial stress MPI. | | Posted | | Number | 95% Confidence Interval | proportion of participants | | Day 1 (stress MPI 1) and Day 2 - 15 (stress MPI 2) | | | | ID | Title | Description |
|---|
| OG000 | Regadenoson After Peak Exercise | On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI. | | OG001 | Regadenoson Alone | On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI. |
|
| Secondary | Proportion of Participants With Agreement in the Summed Stress Score (SSS) Between First and Second Stress Scans | The 17-segment model for standardized myocardial segmentation was used to analyze MPI scans. Each segment was scored on a 0 to 4 scale according to the amount of contrast or radiotracer the myocardium in the segment absorbed:
- 0: normal perfusion
- 1: slightly reduced contrast/radiotracer uptake
- 2: moderately reduced contrast/radiotracer uptake
- 3: severely reduced contrast/radiotracer uptake
- 4: absent contrast/radiotracer uptake.
The Summed Stress Score (SSS) was calculated as the sum of the stress scores across the 17 segments. The mean value (rounded to the nearest integer) across the 3 readers was computed and the SSS was categorized into 4 group categorical variables based on the score: 0 to 3, 4 to 7, 8 to 11, and ≥ 12. The proportion of participants with agreement in respect to these categories between the two stress scans was calculated. | | Posted | | Number | | proportion of participants | | Day 1 (stress MPI 1) and Day 2 - 15 (stress MPI 2) | | | | ID | Title | Description |
|---|
| OG000 | Regadenoson After Peak Exercise | On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI. | | OG001 | Regadenoson Alone | On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI. |
|
| Secondary | Proportion of Participants With Agreement in the Summed Difference Score (SDS) Between First and Second Stress Scans | The 17-segment model for standardized myocardial segmentation was used to analyze MPI scans. At rest and stress, each segment was scored on a 0 to 4 scale according to the amount of contrast or radiotracer the myocardium in the segment absorbed:
- 0: normal perfusion
- 1: slightly reduced contrast/ uptake
- 2: moderately reduced contrast/uptake
- 3: severely reduced contrast/uptake
- 4: absent contrast/uptake.
SSS was calculated as the sum of the stress scores across the 17 segments and the Summed Rest Score (SRS) was calculated as the sum of the rest scores across the 17 segments. The Summed Difference Score (SDS) is the difference in the SSS and SRS (SSS - SRS). The mean value (rounded to the nearest integer) across the 3 readers was computed and the SDS was categorized into 3 categorical variables based on the score: 0 to 6, 7 to 13 and ≥ 14. The proportion of participants with agreement in respect to these categories between the two stress scans was calculated. | | Posted | | Number | | participants | | Day 1 (rest MPI and stress MPI 1) and Day 2 - 15 (stress MPI 2) | | | | ID | Title | Description |
|---|
| OG000 | REG APEX: MPI 2 SDS 0-6 | Participants in the Regadenoson After Peak Exercise (APEX) group who had an SDS from 0 to 6 on their second stress scan. | | OG001 | REG APEX: MPI 2 7-13 | Participants in the Regadenoson After Peak Exercise (REG APEX) group who had an SDS from 7 to 13 on their second stress scan. |
|
| Secondary | Participants With Less, the Same, or More Reversible Perfusion Defects Shown by the First Stress Scan When Compared to the Second Stress Scan | Each reader evaluated the initial stress SPECT MPI scan compared to the participant's second stress SPECT MPI scan (blinded at time of the evaluation) for whether there was Less (-1), the Same (0) or More (1) reversible perfusion defects. The median assessment of the 3 blinded readers was used to summarize the number of participants in each category. | | Posted | | Number | | participants | | Day 1 (stress MPI 1) and Day 2-15 (stress MPI 2) | | | | ID | Title | Description |
|---|
| OG000 | Regadenoson After Peak Exercise | On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI. | | OG001 | Regadenoson Alone | On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI. |
| |
| Secondary | Overall Assessment of Image Quality | The image quality for each scan was rated by each independent reader as 1 = Poor, 2 = Fair, 3 = Good, 4 = Excellent. Based on the median rating of overall image quality across the three readers, the number of participants with each rating is reported for each scan. | | Posted | | Number | | participants | | Day 1 (rest MPI and stress MPI 1) and Day 2 - 15 (stress MPI 2) | | | | ID | Title | Description |
|---|
| OG000 | Regadenoson After Peak Exercise | On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI. | | OG001 | Regadenoson Alone | On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI. |
| |
| Secondary | Target to Background Radiotracer Uptake Ratios From the First and Second Stress Scans | Image quality was assessed through radiotracer uptake in the heart (target organ) compared to liver, gut and combined liver plus gut (background interference). | Full analysis set participants who have planar images available for each scan | Posted | | Mean | Standard Deviation | ratio | | Day 1 (stress MPI 1) and Day 2 - 15 (stress MPI 2) | | | | ID | Title | Description |
|---|
| OG000 | Regadenoson After Peak Exercise: MPI 1 | On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI. | | OG001 | Regadenoson After Peak Exercise: MPI 2 | On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI. | | OG002 | Regadenoson Alone: MPI 1 | On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI. |
|
| Secondary | Percentage of Scans With Subdiaphragmatic Interference | Each reader assessed the sub-diaphragmatic radiotracer interference with cardiac image quality using a 4-point scale of 0 = none, 1 = slight, 2 = moderate or 3 = severe for each stress SPECT MPI. The median rating across the 3 readers was used to summarize the percentage of scans with interference. | | Posted | | Number | | percentage of stress MPI scans | | Day 1 (stress MPI 1) and Day 2 -15 (stress MPI 2) | | | | ID | Title | Description |
|---|
| OG000 | Regadenoson After Peak Exercise: MPI 1 | On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI. | | OG001 | Regadenoson After Peak Exercise: MPI 2 | On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI. | | OG002 | Regadenoson Alone: MPI 1 | On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI. |
|
| Secondary | Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity | The number of cardiac segments obscured by the sub-diaphragmatic activity by group by stress SPECT MPI scan and by reader is reported. | | Posted | | Number | | percentage of segments | | Day 1 (stress MPI 1) and Day - 15 (stress MPI 2) | | | | ID | Title | Description |
|---|
| OG000 | Regadenoson After Peak Exercise: MPI 1 | On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI. | | OG001 | Regadenoson After Peak Exercise: MPI 2 | On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI. | | OG002 | Regadenoson Alone: MPI 1 | On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI. |
|
| Secondary | Number of Participants With Adverse Events Within 24 Hours After Administration of Regadenoson | An adverse event is considered "serious" if, in the view of either the investigator or sponsor, it results in any of the following outcomes:
- Results in death,
- Is life threatening,
- Results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions,
- Results in congenital anomaly, or birth defect,
- Requires inpatient hospitalization or leads to prolongation of hospitalization
- Other medically important events.
Relationship to study drug was assessed by the investigator. | | Posted | | Number | | participants | | Up to 24 hours after study drug administration for each stress MPI (Day 1 and Day 2-15) | | | | ID | Title | Description |
|---|
| OG000 | Regadenoson After Peak Exercise: MPI 1 | On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI. | | OG001 | Regadenoson After Peak Exercise: MPI 2 | On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI. |
|